159 related articles for article (PubMed ID: 19004675)
1. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
[TBL] [Abstract][Full Text] [Related]
2. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy.
Liang CC; Liu CH; Lin YL; Liu CJ; Chiang BL; Kao JH
J Med Virol; 2011 Jul; 83(7):1212-20. PubMed ID: 21567425
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response.
Dogra G; Chakravarti A; Kar P; Chawla YK
Hum Immunol; 2011 Oct; 72(10):935-9. PubMed ID: 21756957
[TBL] [Abstract][Full Text] [Related]
4. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
Abdelraheem WM; Hassuna NA; Abuloyoun SM; Abdel Ghany HM; Rizk HA; Abdelwahab SF
Arch Virol; 2016 Sep; 161(9):2473-80. PubMed ID: 27352267
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
7. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.
Gazdik F; Gazdikova K; Laktis K; Okruhlica L; Fejdiova K; Danis D; Pijak MR; Wsolova L; Kajaba I; Kratky A
Bratisl Lek Listy; 2009; 110(2):77-84. PubMed ID: 19408838
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome.
Świątek-Kościelna B; Kałużna E; Strauss E; Januszkiewicz-Lewandowska D; Bereszyńska I; Wysocki J; Rembowska J; Barcińska D; Antosik D; Mozer-Lisewska I; Nowak J
Hum Immunol; 2017 Feb; 78(2):192-200. PubMed ID: 27793650
[TBL] [Abstract][Full Text] [Related]
9. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
10. Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.
El-Karaksy HM; Sharaf SA; Mandour IA; Mogahed EA; Rady NH; El-Mougy FA
Hum Immunol; 2016 Dec; 77(12):1248-1253. PubMed ID: 27660094
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
15. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
[TBL] [Abstract][Full Text] [Related]
17. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Welzel TM; Morgan TR; Bonkovsky HL; Naishadham D; Pfeiffer RM; Wright EC; Hutchinson AA; Crenshaw AT; Bashirova A; Carrington M; Dotrang M; Sterling RK; Lindsay KL; Fontana RJ; Lee WM; Di Bisceglie AM; Ghany MG; Gretch DR; Chanock SJ; Chung RT; O'Brien TR;
Hepatology; 2009 Jun; 49(6):1847-58. PubMed ID: 19434718
[TBL] [Abstract][Full Text] [Related]
18. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
[TBL] [Abstract][Full Text] [Related]
19. [Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].
Kim KT; Han SY; Kim JH; Yoon HA; Baek YH; Kim MJ; Lee SW; Jang JS; Lee JH; Roh MH
Korean J Hepatol; 2008 Mar; 14(1):36-45. PubMed ID: 18367856
[TBL] [Abstract][Full Text] [Related]
20. [Long-term viral response to interferon alpha 2b plus ribavirin in chronic hepatitis C patients during standard therapy].
Adamek A; Adamek J; Juszczyk J; Bereszyńska I
Przegl Epidemiol; 2007; 61(4):765-70. PubMed ID: 18572509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
